Group 1 - The company expects to achieve a net profit of 250 million to 280 million yuan for the first half of 2025, representing a year-on-year growth of 14.39% to 28.12% after deducting non-recurring gains and losses [1] - The forecasted net profit attributable to shareholders is estimated to be between 260 million and 300 million yuan, with a year-on-year increase of 9.2% to 26% [1] - The company plans to repurchase shares using its own funds and a special loan for stock repurchase, with a total amount not less than 80 million yuan and not exceeding 100 million yuan [1] Group 2 - The repurchase price will not exceed 6.6 yuan per share, with an estimated repurchase quantity of approximately 15.15 million shares, accounting for about 0.88% of the current total share capital [2] - The estimated repurchase quantity could be around 12.12 million shares, representing about 0.70% of the total share capital, based on the lower limit of the repurchase funds [2] - The funding for the repurchase will come from the company's own funds and a special loan, with a commitment from China Everbright Bank to provide up to 90 million yuan for the stock repurchase [2]

Group 1: Market Overview - The number of companies listed on the New Third Board increased by 41% in the first half of 2025 compared to the same period last year, reaching 158 companies [1] - As of June 30, 2025, the total number of companies listed on the New Third Board reached 6060 [1] - The average revenue of the newly listed companies was 975 million yuan, with a median of 481 million yuan, while the average net profit was approximately 64 million yuan, with a median of 53 million yuan [1] Group 2: Company Highlights - Guangzhou Pharmaceutical, the company with the largest net profit among the newly listed firms, achieved a revenue of 5.46 billion yuan and a net profit of 578 million yuan in 2024 [2] - The company is a major player in the pharmaceutical supply chain and ranks seventh among national pharmaceutical distribution companies [2] - Among the 158 newly listed companies, 121 are specialized and innovative enterprises, accounting for nearly 80% [2] Group 3: Industry Distribution - The largest number of newly listed companies in the first half of 2025 came from the "Chemical Raw Materials and Chemical Products Manufacturing" sector, with 22 companies [2] - The "Computer, Communication, and Other Electronic Equipment Manufacturing" sector had 18 companies, while the "Specialized Equipment Manufacturing" sector had 15 companies [2] Group 4: Regional Distribution - Guangdong Province led with 30 newly listed companies, followed by Jiangsu Province with 26 and Zhejiang Province with 24 [3] Group 5: Regulatory Changes - The National Equities Exchange and Quotations (NEEQ) revised the "Guidelines for Due Diligence Work of Main Underwriters" to enhance the responsibilities of main underwriters [3][4] - The revised guidelines include new requirements for risk assessment and due diligence, particularly for companies that are not yet profitable [4][5] - The guidelines emphasize that main underwriters must maintain independent responsibility and cannot outsource their legal obligations to third parties [5]

Performance Forecast - The company expects a net profit of 260 million to 300 million yuan for the current reporting period, compared to 238.09 million yuan in the same period last year, indicating a growth of 9.2% to 26% [1] - The expected net profit after deducting non-recurring gains is projected to be between 250 million and 280 million yuan, up from 218.55 million yuan year-on-year, reflecting a growth of 14.39% to 28.12% [1] - Basic earnings per share are anticipated to be between 0.15 yuan and 0.17 yuan, compared to 0.14 yuan per share in the previous year [1] Reasons for Performance Change - The company is following its "14th Five-Year" strategic plan, focusing on the core business of pharmaceutical sales while expanding into medical devices, reagents, traditional Chinese medicine health products, specialty pharmacies, emerging businesses, and third-party reserves [1] - Revenue growth is attributed to both organic development and external mergers and acquisitions, alongside improved network layout [1] - The company has strengthened cost control, resulting in a significant reduction in operating management expenses and financing costs [1]

Mergers and Acquisitions - Dajia Weikang plans to acquire 60.85% equity of Anhui Dajia Weikang Health Pharmacy for a transaction price of 116 million yuan, making it a subsidiary post-transaction [1] - Jizhong Energy intends to purchase 49% equity of Jingneng Xilin Gol Energy for 669 million yuan, with the target company having a construction scale of 2×660MW efficient supercritical indirect air-cooled units [2] - Bomin Electronics has terminated its acquisition plan for Benchuang Electronics due to failure to reach consensus on key transaction terms [3] Shareholding Changes - Jingbeifang's employee shareholding platform plans to reduce its stake by up to 3% of the company's total shares, equating to a maximum of 26 million shares [4] - Sichuan Shuangma's major shareholders plan to collectively reduce their holdings by up to 2.92% of the company's total shares, amounting to approximately 1.11 million shares [5] - Chenghe Technology's shareholder, Shanghai Kehui Investment, intends to reduce its stake by up to 3% of the company's total shares, which is approximately 564,960 shares [6] Earnings Disclosure - China Merchants Heavy Industry expects a significant decline in net profit attributable to shareholders, projecting a decrease of 90.16% to 91.95%, with an estimated profit of 9 million to 11 million yuan [7] - Dongpeng Beverage anticipates a net profit increase of 33.48% to 41.57%, estimating a profit range of 2.31 billion to 2.45 billion yuan for the first half of 2025 [8] - Shuanglu Pharmaceutical forecasts a substantial net profit growth of 237.95% to 356.24%, estimating a profit of 100 million to 135 million yuan for the first half of 2025, primarily due to changes in the fair value of financial assets [10]

Core Points - The document outlines the management measures for independent directors of Chongqing Pharmaceutical Holdings Co., Ltd, aiming to enhance corporate governance and protect the interests of minority shareholders [2][20] - It specifies the qualifications, responsibilities, and operational procedures for independent directors to ensure their independence and effectiveness in decision-making [3][5] Summary by Sections General Principles - The purpose of the measures is to improve corporate governance and regulate the behavior of independent directors [2] - Independent directors must not hold any other positions within the company and should have no direct or indirect interests that could affect their judgment [2][3] - Independent directors are obligated to act in good faith and diligence, ensuring the protection of minority shareholders' rights [3] Qualifications and Appointment - Independent directors must meet specific independence criteria, including not being related to major shareholders or having significant business ties with the company [5][6] - The company must ensure that independent directors constitute at least one-third of the board, including at least one accounting professional [2][3] Responsibilities and Duties - Independent directors are responsible for participating in board decisions, supervising potential conflicts of interest, and providing professional advice [8][10] - They have the authority to independently hire external consultants for audits or consultations [8][10] Operational Procedures - Independent directors must attend board meetings and can delegate their voting rights if unable to attend [9][10] - They are required to submit annual reports detailing their attendance, participation in committees, and communication with minority shareholders [14][15] Support and Resources - The company must provide necessary support and resources for independent directors to fulfill their duties effectively [17][19] - Independent directors are entitled to reasonable compensation and may have access to liability insurance [19][20]

General Principles - The purpose of the rules is to standardize the board meeting procedures and improve the efficiency and scientific decision-making of the board [1] - The board of directors is the decision-making body for the company's management, responsible for the company's development goals and major operational activities [1][2] Board Composition and Qualifications - The board consists of 11 directors, including 4 independent directors [3] - Directors must be natural persons and cannot hold office if they meet certain disqualifying conditions, such as criminal convictions or bankruptcy responsibilities [2][3] Board Operations - Directors are elected by the shareholders for a term of three years and can be re-elected [3] - The board can increase or decrease its members based on business needs, but any changes must be approved by the shareholders [4] - Directors who fail to attend meetings without proper delegation may be recommended for replacement [4] Responsibilities and Powers of the Board - The board has the authority to convene shareholder meetings, execute resolutions, and decide on major operational plans and investment proposals [6][7] - The chairman of the board is responsible for presiding over meetings and ensuring the execution of board resolutions [22][24] Independent Directors - Independent directors must account for at least one-third of the board and include at least one accounting professional [9][10] - The nomination and election of independent directors must comply with relevant regulations and be disclosed to shareholders [10][11] Committees of the Board - The board establishes specialized committees, including the Strategy and Sustainable Development Committee, Audit and Risk Committee, Nomination Committee, and Compensation and Assessment Committee [14][15] - Each committee is responsible for specific functions and must report to the board [14][15] Board Meetings - The board must hold at least two meetings annually, with proper notice provided to all directors [19][20] - Decisions require a majority vote from attending directors, and specific procedures must be followed for related party transactions [22][23] Documentation and Compliance - Meeting minutes must be recorded and maintained for at least ten years, and decisions made must comply with legal and regulatory requirements [24][25] - The board secretary is responsible for managing documentation, coordinating meetings, and ensuring compliance with disclosure obligations [15][16]

General Provisions - The company aims to protect the legal rights of shareholders, employees, and creditors while ensuring the preservation and appreciation of state-owned assets, in accordance with relevant laws and regulations [1] - The company is established as a joint-stock limited company approved by the Chongqing Municipal Government and registered with the Chongqing Market Supervision Administration [2] - The company was approved by the China Securities Regulatory Commission for its initial public offering of 55 million shares, listed on the Shenzhen Stock Exchange [3] Company Structure - The registered capital of the company is RMB 1,728,184,696 [2] - The company is a permanent joint-stock limited company, with the chairman serving as the legal representative [2] - The legal representative's civil activities conducted on behalf of the company will have legal consequences for the company [2] Governance and Management - The company establishes a party committee in accordance with the Communist Party of China regulations, which plays a leading role in corporate governance [3] - The company implements a dual-entry and cross-appointment leadership system, allowing qualified members of the party committee to enter the board of directors and management [4] Business Objectives and Scope - The company's business objective is to provide comprehensive pharmaceutical services, ensuring the public has access to safe medications, and to achieve integrated development in the pharmaceutical industry [5] - The company is engaged in various licensed activities, including drug production, transportation, and investment in pharmaceutical research and sales projects [5] Share Issuance and Management - The company's shares are issued in the form of stocks, adhering to principles of openness, fairness, and justice [6] - The total number of shares issued by the company is 1,728,184,696, all of which are ordinary shares denominated in RMB [6] Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends and participate in decision-making processes, including the right to propose and vote on resolutions at shareholder meetings [11][12] - Shareholders are obligated to comply with laws and regulations, pay for their subscribed shares, and not misuse their rights to harm the company or other shareholders [16] Shareholder Meetings - The company holds annual and temporary shareholder meetings, with the annual meeting required to be held within six months after the end of the previous fiscal year [20] - The company must provide legal opinions on the legality of the meeting's procedures and resolutions [21] Voting and Resolutions - Resolutions at shareholder meetings can be classified as ordinary or special, with ordinary resolutions requiring a simple majority and special resolutions requiring a two-thirds majority [32] - The company must ensure that voting results, especially those affecting minority investors, are disclosed promptly [33]

Core Viewpoint - The establishment of the Audit and Risk Committee aims to enhance the decision-making function of the board of directors, ensuring effective supervision of the management team and improving corporate governance structure [1]. Group 1: Committee Structure - The committee consists of three directors, all of whom are external directors, including two independent directors, with an accounting professional serving as the convener [2]. - The committee members must possess the necessary professional knowledge and experience to effectively supervise and evaluate internal and external audit work [2]. Group 2: Responsibilities and Authority - The main responsibilities of the committee include supervising and evaluating external and internal audit work, reviewing financial information and disclosures, and overseeing internal controls [3]. - The committee has the authority to propose the hiring or replacement of external audit firms and to supervise the actions of directors and senior management [3][4]. Group 3: Meeting Procedures - The committee is required to meet at least once a quarter, with provisions for special meetings as needed [6][8]. - A quorum for meetings requires the presence of at least two-thirds of the committee members, and decisions must be approved by a majority [8][9]. Group 4: Reporting and Accountability - The committee must review the company's financial reports and ensure their authenticity, accuracy, and completeness, focusing on significant accounting and auditing issues [5]. - The committee is responsible for reporting any violations of laws or regulations by directors or senior management to the board or shareholders [5][6].

Core Viewpoint - The company plans to repurchase shares to reduce registered capital, with a total repurchase amount between RMB 80 million and RMB 100 million, and a maximum price of RMB 6.6 per share [1][3][4] Summary by Relevant Sections Repurchase Purpose and Amount - The repurchased shares will be used to reduce the company's registered capital [1] - The total repurchase amount is set between RMB 80 million and RMB 100 million [1][4] Funding and Price - The funding sources for the repurchase will be the company's own funds and a special loan for stock repurchase [1][4] - The maximum repurchase price is capped at RMB 6.6 per share [1][3] Expected Repurchase Quantity - The estimated number of shares to be repurchased is approximately 15,151,515 shares, accounting for about 0.88% of the current total share capital of 1,728,184,696 shares [1][4] - The estimated range for the number of shares is between 12,121,212 and 15,151,515 shares [4][5] Repurchase Method and Duration - The repurchase will be conducted through the Shenzhen Stock Exchange trading system via centralized bidding [1][3] - The duration for the repurchase is set for 12 months from the date of approval by the shareholders' meeting [1][3] Compliance and Conditions - The repurchase plan must be approved by the shareholders' meeting, and there are risks associated with not obtaining this approval [2][9] - The company has received a loan commitment from China Everbright Bank for up to RMB 90 million for the repurchase [4][6] Impact on Company Structure - Post-repurchase, the company's total share capital will decrease, with the number of circulating shares expected to be reduced accordingly [5][6] - The management believes that the repurchase will not adversely affect the company's operational, financial, or developmental capabilities [6][7] Management Commitments - The board of directors commits to maintaining the interests of all shareholders and creditors, ensuring that the repurchase does not harm the company's debt repayment ability or ongoing operations [7][8]

Group 1 - The fourth session of the Supervisory Board of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd. was held on July 11, 2025, with all three supervisors present [1][2] - The Supervisory Board approved the adjustment of the price related to the 2023 restricted stock and stock option incentive plan, in compliance with relevant laws and regulations [1][2] - The decision to cancel part of the restricted stock and revoke some stock options was also approved, ensuring no substantial impact on the company's financial status or operational results [2] Group 2 - The voting results showed unanimous support with 3 votes in favor, and no votes against or abstentions [2] - The adjustments made do not require submission to the shareholders' meeting as authorized by the first temporary shareholders' meeting of 2024 [1][2]